{"id":"prc-063-oral-capsules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By increasing the levels of serotonin and norepinephrine, PRC-063 oral capsules help to improve mood, reduce pain, and increase energy levels. This is achieved by blocking the reuptake of these neurotransmitters, allowing them to remain in the synaptic cleft for a longer period and increasing their availability for binding to their respective receptors.","oneSentence":"PRC-063 oral capsules are a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:53.033Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain"},{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT03618030","phase":"PHASE3","title":"PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2018-08-21","conditions":"ADHD","enrollment":288},{"nctId":"NCT03172481","phase":"PHASE3","title":"PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2017-05-01","conditions":"ADHD","enrollment":156},{"nctId":"NCT02139124","phase":"PHASE3","title":"The Efficacy and Safety of PRC-063 in Adult ADHD Patients","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2014-04","conditions":"ADHD","enrollment":375},{"nctId":"NCT02555150","phase":"PHASE3","title":"A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2015-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":40},{"nctId":"NCT02225639","phase":"PHASE3","title":"PRC-063 in an ADULT Workplace Environment","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2014-08","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":60},{"nctId":"NCT02139111","phase":"PHASE3","title":"PRC-063 in Adolescent ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2014-04","conditions":"ADHD","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PRC-063 oral capsules","genericName":"PRC-063 oral capsules","companyName":"Purdue Pharma, Canada","companyId":"purdue-pharma-canada","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PRC-063 oral capsules are a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain. Used for Chronic pain, Major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}